BCLI / BrainStorm shares plunge 56% after FDA advisers reject ALS cell therapy

Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) plummeted by 56% in early trading after the company's treatment for amyotrophic lateral scle more_horizontal

BrainStorm Cell Therapeutics Inc. BCLI, -8.35% shares fell 56% premarket on Thursday after advisors to the U.S. Food and Drug Administration on Wednes more_horizontal

A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics BCLI, -8.35% for amyotrophic latera more_horizontal

The U.S. health regulator's advisers on Wednesday voted against BrainStorm Cell Therapeutics' therapy for patients with amyotrophic lateral sclerosis more_horizontal

Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell almost 40% on Monday morning after Food and Drug Administration (FDA) staff reviewers e more_horizontal

The U.S. Food and Drug Administration's staff reviewers raised concerns on Monday over the safety and efficacy of BrainStorm Cell Therapeutics' amyotr more_horizontal

BCLI has completed a phase 3 trial in ALS. Despite not meeting the primary endpoint BCLI is still applying for approval and an AdCom meeting is schedu more_horizontal

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. more_horizontal